Market open · Delayed intraday data · 2:10 PM ET
Last update: Nov 18, 2026, 2:02 PM ET
Market open·54 changes confirmed today

Track the stock moves that actually matter.

BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.

1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
See all of today's movers: top gainers, losers and trending tickers →

Investment research built around change detection.

Showing:

BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.

Market open - Last update: Nov 18, 2026, 10:08 AM ET
TGT
Target Corporation
$171.12
EPS surprise+27.40%
Nov 18, 2026 ET
🏆Material / Earnings✓High confidence Research available →

What changed: Target Corporation (TGT) reported EPS of $2.65 vs. consensus estimate of $2.08, beating estimates by 27.4% on 2026-11-18.

Source: earnings_events

Changes History →
What's next

TGT earnings scheduled for 2027-03-02, with consensus EPS estimate of $2.70.

Market open - Last update: Nov 18, 2026, 10:08 AM ET
LOW
Lowe's Companies, Inc.
$222.06
EPS surprise+7.64%
Nov 18, 2026 ET
🏆Material / Earnings✓High confidence

What changed: Lowe's Companies, Inc. (LOW) reported EPS of $3.10 vs. $2.88 consensus estimate, beating by 7.6% when results were announced on November 18, 2026.

Source: earnings_events

Changes History →
What's next

Monitor for analyst rating or price-target updates in the days following the earnings announcement.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
ELV
Elevance Health Inc.
$404.05
▼ 6.89%
Prev close $433.93
Nov 18, 2026 ET
📊Valuation

What changed: Elevance Health fell 5.26% to $411.09, driven by sector-wide managed-care and Medicaid margin concerns alongside medical cost trend anxiety (elevated ACA and Medicaid claim utilization), per web research. Volume of 551,891 shares in the first 120 minutes represents 1.29x the historical average for this time of day, indicating normal participation for the intraday period.

Detected Nov 18, 2:00 PM ET

Source: Yahoo Finance ↗

Changes History →
What's next

ELV earnings scheduled for January 27, 2027 (consensus EPS estimate $2.08); also monitor Medicaid utilization trends and updates on cost management initiatives that could signal progress toward the projected 2027 margin recovery.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
TTWO
Take-Two Interactive Software, Inc.
$221.83
▲ 8.78%
Prev close $203.93
Nov 18, 2026 ET
📊Valuation⚡Activity
Intraday updates2 updates
2:00 PM ETLATESTValuation✓ High confidence

Take-Two Interactive shares surged 7.10% to $218.41 on the imminent midnight release and near-perfect critical reviews of Grand Theft Auto VI, with early scores including rare 10/10 ratings from major outlets (Reuters, Benzinga). Volume traded 4.67x the historical average at this time of day, with pre-orders tracking well above initial expectations ahead of the official launch.

Source: Reuters ↗

11:30 AM ETActivity✓ High confidence

Take-Two jumped 6.52% to $217.23 on anticipation of Grand Theft Auto VI's imminent release, with near-perfect critical reviews driving investor sentiment (Reuters, Benzinga). Volume surged to 7.43x the historical average for this time of day, suggesting broad retail and institutional participation in the rally. The move caps a volatile pre-launch period in which TTWO had fallen 10% over the prior two days.

Source: Reuters ↗

Changes History →
What's next

Take-Two's Q3 FY2027 earnings (scheduled ~2027-02-02) for GTA VI launch-week revenue, player metrics, and full-year guidance; also monitor early player reviews and engagement data in the 48–72 hours post-release.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
ASTS
AST SpaceMobile, Inc.
$25.87
▼ 6.23%
Prev close $27.59
Nov 18, 2026 ET
📊Valuation
Intraday updates1 update
2:00 PM ETLATESTValuation✓ High confidence

AST SpaceMobile fell 7.65% to $25.48 following analyst downgrade and renewed concerns over launch delays. Seeking Alpha published a rating downgrade citing a 'launch bottleneck,' while Motley Fool noted the company has pushed its launch target to 2027 and the stock is trading 78% below its all-time high. Volume of 9.3M shares ran 1.41x the intraday average, indicating elevated selling pressure.

Source: 247wallst.com ↗

Changes History →
What's next

ASTS earnings on 2026-03-01 (consensus EPS estimate −$0.36); any updates on launch timeline, Blacklift partnership status, or spectrum regulatory approvals.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
FCX
Freeport-McMoRan Inc.
$51.61
▼ 6.67%
Prev close $55.30
Nov 18, 2026 ET
📊Valuation

What changed: Freeport-McMoRan fell 5.75% to $52.12, driven by a combination of subsidiary debt news and analyst downgrade. PT Freeport Indonesia (FCX's 48.76%-owned subsidiary) priced $750 million of senior notes due 2033 at 6.90%, raising debt refinancing concerns, while Erste Group Bank downgraded FCX from buy to hold on November 18, 2026. The decline reflects broader pressure on copper miners amid commodity price volatility.

Detected Nov 18, 2:00 PM ET

Source: Yahoo Finance ↗

Changes History →
What's next

FCX earnings on 2027-01-28 (consensus EPS estimate $1.01); monitor copper price trends and any updates on PT Freeport Indonesia's debt service or project developments.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
RBLX
Roblox Corporation
$47.05
▲ 6.93%
Prev close $44.00
Nov 18, 2026 ET
📊Valuation

What changed: Roblox rose 8.27% to $47.64 intraday, though the specific catalyst was not disclosed in available evidence. Finance.yahoo.com articles were cited as sources for today's movement, but their precise content—whether earnings-related, product news, or other developments—could not be verified from the provided data. Volume of 3.6M shares ran at 0.81x the historical average, consistent with normal mid-session trading.

Detected Nov 18, 2:00 PM ET

Source: Yahoo Finance ↗

Changes History →
What's next

RBLX earnings on 2027-02-04 (consensus EPS estimate: −$0.50); monitor for any announcements or updates to explain today's intraday surge.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
CBRS
Cerebras Systems Inc.
$94.65
▼ 9.15%
Prev close $104.18
Nov 18, 2026 ET
📊Valuation🛡Risk
Intraday updates2 updates
2:00 PM ETLATESTValuation✓ High confidence

Cerebras Systems fell 7.71% to $96.15 following a cascade of analyst price-target cuts post-earnings, combined with an active shareholder investigation and insider selling pressure. UBS cut its target to $155 from $250, Needham to $200 from $300, and Mizuho to $240 from $300 (per web catalyst synthesis). Volume reached 6.39M shares, 1.33x the time-adjusted average, reflecting elevated trading activity amid sector-wide AI infrastructure caution.

Source: Seeking Alpha ↗

11:30 AM ETRisk✓ High confidence

Cerebras Systems fell 6.25% to $97.67 on elevated volume (2.04x normal for this time of day), with 4.3M shares traded in the first 65 minutes of the session. No specific catalyst emerged from available sources; the move occurs as a Seeking Alpha analyst rates the stock a Strong Buy at 45% below its IPO price, suggesting a potential disconnect between technical selling pressure and fundamental valuation.

Source: Seeking Alpha ↗

Changes History →
What's next

Watch for the conclusion or outcome of the Pomerantz shareholder investigation, any further insider-sale filings, and guidance or earnings commentary from management on competitive positioning and gross-margin trajectory.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
CRWD
CrowdStrike Holdings, Inc.
$239.43
▲ 9.04%
Prev close $219.58
Nov 18, 2026 ET
📊Valuation

What changed: CrowdStrike rallied +5.12% to $230.83, driven by a broader AI sector rebound following Nvidia's earnings beat on Tuesday and bullish analyst upgrades ahead of CRWD's own quarterly report (Investing.com). Volume ran 1.84x expected at this point in the session, consistent with normal intraday patterns.

Detected Nov 18, 2:00 PM ET

Source: Investing.com ↗

Changes History →
What's next

CrowdStrike fiscal Q3 earnings on December 1, 2026 (consensus EPS: $0.31); monitor whether analyst upgrades continue or if any pre-earnings revisions emerge.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
PANW
Palo Alto Networks, Inc.
$334.33
▲ 8.10%
Prev close $309.29
Nov 18, 2026 ET
📊Valuation⚡Activity
Intraday updates2 updates
2:00 PM ETLATESTValuation✓ High confidence

Palo Alto Networks rallied +5.22% to $325.43 as investors positioned ahead of Q1 FY2027 earnings (due after market close today) on pre-earnings optimism and bullish analyst revisions, per Benzinga. Volume surged to 2.46M shares, 2.41x the expected rate at this time of day. The move also benefited from a broader tech rebound following Nvidia's earnings, per the web catalyst.

Source: invezz.com ↗

10:30 AM ETActivity✓ High confidence

Palo Alto Networks surged +5.82% to $327.29 as the market ahead of imminent earnings, with analyst revisions and technical positioning drawing attention per Benzinga. Volume ran 2.43x the 60-minute average, signaling elevated retail and institutional interest into the event.

Source: invezz.com ↗

Changes History →
What's next

Palo Alto Networks Q1 FY2027 earnings release and earnings call after market close today (November 18, 2026).

Market open - Last update: Nov 18, 2026, 2:00 PM ET
PODD
Insulet Corp.
$141.07
▼ 2.94%
Prev close $145.34
Nov 18, 2026 ET
📊Valuation

What changed: An Insulet analyst downgrade drove the intraday decline. Benzinga reported the company among top five downgrades for the session, with at least one analyst no longer bullish on PODD. The stock fell 2.94% to $141.07 on below-average volume (0.64x expected at 270 minutes into the session), suggesting limited institutional participation in the selloff.

Detected Nov 18, 2:00 PM ET

Source: Seeking Alpha ↗

Changes History →
What's next

Insulet's Q4 2026 earnings release (2027-02-17) and the full text of the downgrade rationale from the analyst who withdrew bullish coverage.

Market open - Last update: Nov 18, 2026, 2:00 PM ET
DELL
Dell Technologies Inc.
$314.55
▼ 2.55%
Prev close $322.79
Nov 18, 2026 ET
📊Valuation

What changed: Dell reversed a 5% premarket gain to trade -2.83% after GF Securities cut its price target from $497 to $341, citing headwinds in enterprise servers, PCs, and lost AI server orders (including a portion of SpaceX's VR200 to Hon Hai). Stock fell from $322.79 to $313.65 on normal-volume trading (1.04x average), erasing earlier momentum from Nvidia's earnings beat and a Citi buy endorsement.

Detected Nov 18, 2:00 PM ET

Source: defenseworld.net ↗

Changes History →
What's next

Dell earnings on November 24, 2026; consensus EPS estimate $6.60. Watch for management commentary on AI server demand, SpaceX orders, and enterprise margin trajectory.

Latest research

View all research →

In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.

Target (TGT) share-price line rising toward a 52-week high on an abstract background, marking a traffic-led fiscal Q3 earnings beat and raised sales guidance.
Stock AnalysisNovember 18, 2026 · 11 min read

Target (TGT) Jumps Toward a 52-Week High on a Traffic-Led Q3 Beat and a Raised Sales Outlook

Target (TGT) jumped more than 5% on November 18, pushing toward its 52-week high after a traffic-led fiscal third-quarter beat — a gain that substantially outpaced flat big-box peers and the broad market. EPS of $2.65 (GAAP and adjusted alike) cleared the ~$2.07 expected, but about $0.50 came from a one-time $301 million tariff refund, leaving underlying EPS near $2.15 (still up ~21% year over year). What mattered more was the mix: comparable sales rose 5.6%, driven by a 5.0% gain in traffic — more shoppers, the proof point for a company whose slump was a traffic problem — though the category recovery stayed uneven, with apparel and home soft. Target also raised its full-year sales-growth outlook to around 6%. The catch is price: after more than doubling off an $83 low, the stock sits near its 52-week high and above the analysts' average target of ~$165.56, with only a Hold consensus, so much of the initial re-rating may already be reflected and the holiday quarter now has to confirm the recovery.

Walt Disney (DIS) share-price line rising toward a 52-week high on an abstract background, marking a fiscal Q4 earnings beat, doubled streaming profit, and a dividend increase.
Stock AnalysisNovember 17, 2026 · 11 min read

Disney (DIS) Nears a 52-Week High on a Q4 Beat, a 33% Dividend Hike, and a $3 Billion Savings Target

The Walt Disney Company rose about 2.5% to roughly $122 — within about 1% of a 52-week high — on November 17 after reporting fiscal fourth-quarter results, outperforming flat media peers and the broader market. Revenue rose 16% to $25.9 billion (though an extra 53rd week flatters that to roughly 8% underlying) and adjusted EPS of $1.77 beat expectations, with the standout being streaming: operating income more than doubled to $824 million (about +65% excluding the extra week), confirming the direct-to-consumer business is becoming meaningfully profitable. Management paired the beat with a shareholder-friendly message — a 33% dividend increase (to $2.00 a year) and a target of about $3 billion in annual cost savings by fiscal 2029 — while reaffirming double-digit adjusted-EPS growth in fiscal 2027 and, notably, raising content spending ~9% to roughly $26 billion, so this is still a growth-and-invest story. The turnaround, initiated under Bob Iger and now led by CEO Josh D'Amaro, is clearly working — but the catch is price: the stock has risen ~14% in a year to near its 52-week high, with only ~5% upside to the average analyst target, so much of it is already in the shares.

A deep-navy data card reading 'DoorDash + Instacart, $17B deal meets the DOJ' with the tickers DASH and CART, a number line showing Instacart's $58.66 price below the $65 offer, and an antitrust-gavel motif, marking the DOJ-led review of the acquisition.
Stock AnalysisNovember 17, 2026 · 9 min read

DoorDash's $17 Billion Instacart Takeover Heads to a DOJ Antitrust Review

DoorDash's roughly $17 billion, $65-a-share acquisition of Instacart now heads to a U.S. Department of Justice antitrust review, Reuters and Bloomberg reported — the DOJ, not the FTC, taking the lead on a deal to combine the top restaurant-delivery and online-grocery platforms. A review is not a challenge, and both companies still target a late-2027/early-2028 close, but with CART near $59 versus the $65 offer, the ~11% spread tells the real story: time, regulatory risk, and a stock-heavy slice of the consideration that floats with a falling DoorDash.

DASHCARTRead →
Summit Therapeutics (SMMT) share-price line falling sharply on an abstract background, marking an FDA Complete Response Letter for ivonescimab.
Stock AnalysisNovember 16, 2026 · 12 min read

Summit Therapeutics (SMMT) Plunges ~16% to a 52-Week Low After the FDA Rejects Ivonescimab's First US Filing

Summit Therapeutics plunged about 16% to roughly $11.82 — a fresh 52-week low — on November 16 after disclosing that the FDA had issued a Complete Response Letter (a rejection, for now) for its lead drug, ivonescimab. The move was emphatically company-specific: on a day the broad market and biotech indexes each fell about 2%, Summit dropped eight times as hard. The CRL covers ivonescimab plus chemotherapy after EGFR-targeted treatment in non-small cell lung cancer, from the Phase 3 HARMONi trial — which clearly met its progression-free survival goal (6.8 vs 4.4 months) but whose primary overall-survival analysis narrowly missed significance (16.8 vs 14.0 months, HR 0.79, p=0.057), and the FDA judged the benefit-risk insufficient. Crucially, this is not a verdict that the drug fails to extend life: in a separate first-line trial (China's HARMONi-2) ivonescimab beat Keytruda on overall survival (30.8 vs 22.6 months, HR 0.73, p=0.009). Several things keep the CRL from being thesis-ending: it covers one smaller indication; the far larger global first-line opportunity (HARMONi-3, HARMONi-7) is still ahead; and just six weeks earlier AstraZeneca completed a $2 billion strategic investment in Summit. Even after the drop, Summit is a ~$9.4 billion company with roughly $2.6 billion of liquidity (including the AstraZeneca cash) and ~27%-of-float short interest — a well-funded, AstraZeneca-backed, polarizing bet whose value rests almost entirely on first-line survival data still to come.

Tyson Foods (TSN) share-price line rising on an abstract background, marking a better-than-feared Q4 and a 2027 beef-recovery outlook.
Stock AnalysisNovember 16, 2026 · 11 min read

Tyson Foods (TSN) Jumps ~7% on a Better-Than-Feared Q4 and an Outlook for Sharply Narrower Beef Losses

Tyson Foods jumped about 7% to roughly $62.80 on November 16 after reporting fiscal fourth-quarter results — and it did so on a risk-off day, with the S&P 500 down nearly 2% as the AI, chip and crypto trades sold off. For a defensive consumer-staples name to rise ~7% while the market fell is a clear company-specific signal, reinforced by a rotation into cheap, low-beta stocks. Tyson's adjusted EPS of $0.61 was roughly in line with or slightly above commonly cited consensus estimates, but it was down ~47% year over year, and on a GAAP basis the company posted a $0.22-per-share loss; revenue of $14.6 billion beat but underlying sales fell ~4%, and adjusted operating income dropped 41%. What drove the jump was the outlook — specifically for beef: management guided its Beef segment from a $654 million fiscal-2026 loss toward roughly breakeven in 2027 (a $300 million loss to a $100 million profit), a sharp narrowing of the biggest drag on earnings caused by a historic cattle shortage, even though total-company adjusted operating-income guidance ($1.7–$2.15 billion) is roughly flat versus this year's $1.977 billion. The stock looks cheap on sales (~0.4x) and reasonable on forward earnings (~16x), but after the pop it sits right at the analysts' average target with a Hold rating — so the move reads as a weak-but-better-than-feared quarter plus a credible beef-loss turn, re-rating a beaten-down defensive in one session.